末梢動脈疾患（PAD）の世界市場：競合情勢

• GlobalDataによるPADの疫学予測では、対象16ヶ国において2024年に1,800万人超がPAD有病者と診断されると予測されています。
• PADの上市済み薬品には主に、凝固第X因子阻害薬、フィブリノゲン活性化薬、肝細胞増殖因子活性化薬、血管内皮増殖因子活性化薬が含まれます。
• PADのパイプラインには主に、受容体作動薬、次いで生物学的因子活性化薬、酵素阻害薬が含まれます。
• フェーズ3試験の大半は、商業スポンサーによって支援されており、学術スポンサーは主にフェーズII試験を実施しています。
• 過去10年間に発生したPAD開発企業の取引では、北米ではパートナーシップと買収がもっとも多く、欧州とアジア太平洋では買収が主流でした。

当レポートでは、世界の末梢動脈疾患（PAD）市場について調査分析し、疾患の情勢、上市済み薬品とパイプライン薬品の評価、現在と将来の競合情勢などを提供しています。

目次

第1章 序文

第2章 主な調査結果

第3章 疾患の情勢

• 疾患の概要
• 疫学の概要
• 治療の概要

第4章 上市済み薬品の評価

• 主な上市済み薬品
• 概要：作用機序別
• 概要：投与経路別
• 上市済み薬品のプロファイルと売上の予測

第5章 価格設定と償還の評価

• 年間治療費
• 価格設定と償還までの時間

第6章 パイプライン薬品の評価

• フェーズIIIパイプライン薬品
• 概要：開発段階別
• 概要：分子タイプ別
• 概要：作用機序別
• 概要：投与経路別
• 薬品固有のフェーズ移行成功率（PTSR）と承認可能性（LoA）
• 治療領域と適応症固有のPTSRとLoA

第7章 臨床試験の評価

• 過去の概要
• 概要：フェーズ別
• 概要：ステータス別
• 概要：フェーズ別（進行中/計画済みの試験）
• 仮想コンポーネントによる試験
• 地理的概要
• 単一国/多国間試験：地域別
• スポンサー上位20社と内訳：フェーズ別
• スポンサー上位20社と内訳：ステータス別
• 概要：エンドポイントステータス別
• 概要：人種/民族別
• 登録データ
• 試験施設の上位20ヶ国
• 世界の上位20施設
• 実現可能性分析 - 地理的概要
• 実現可能性分析 - ベンチマークモデル

第8章 取引情勢

• 合併、買収、戦略的提携：地域別
• 近年の合併、買収、戦略的提携

第9章 商業的評価

• 主要市場企業

第10章 将来の市場カタリスト

第11章 付録

This reports provides a data-driven overview of the current and future competitive landscape in PAD therapeutics.

• More than 18,000,000 diagnosed prevalent cases of PAD are expected in 2024 in the 16 countries covered in GlobalData's epidemiology forecast for PAD.
• The innovator marketed drugs space for PAD includes coagulation factor X inhibitors, fibrinogen activators, hepatocyte growth factor activators, and vascular endothelial growth factor activators, amongst others.
• The PAD pipeline mainly includes receptor agonists, followed by biological factor activators and enzyme inhibitors.
• The majority of Phase III trials were backed by commercial sponsors, academic sponsors mostly conducted Phase II trials.
• In deals involving companies developing PAD assets that occurred during past 10 years, Partnerships and acquisitions were the most prevalent deal type in North America, acquisitions dominated in Europe and Asia-Pacific.

Scope

GlobalData's PAD: Competitive Landscape combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.

Components of the report include -

• Disease Landscape
• Disease Overview
• Epidemiology Overview
• Treatment Overview
• Marketed Products Assessment
• Breakdown by Mechanism of Action, Route of Administration
• Product Profiles with Sales Forecast
• Pricing and Reimbursement Assessment
• Annual Therapy Cost
• Time to Pricing and Time to Reimbursement
• Pipeline Assessment
• Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
• Product Profiles with Sales Forecast
• Late-to-mid-stage Pipeline Drugs
• Phase Transition Success Rate and Likelihood of Approval
• Clinical Trials Assessment
• Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
• Enrolment Analytics, Site Analytics, Feasibility Analysis
• Deals Landscape
• Mergers, Acquisitions, and Strategic Alliances by Region
• Overview of Recent Deals
• Commercial Assessment
• Key Market Players
• Future Market Catalysts

Reasons to Buy

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the PAD market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global PAD market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Table of Contents

Table of Contents

1 Preface

• 1.1 Contents
• 1.2 Report Scope
• 1.3 List of Tables and Figures
• 1.4 Abbreviations

2 Key Findings

3 Disease Landscape

• 3.1 Disease Overview
• 3.2 Epidemiology Overview
• 3.3 Treatment Overview

4 Marketed Drugs Assessment

• 4.1 Leading Marketed Drugs
• 4.2 Overview by Mechanism of Action
• 4.3 Overview by Route of Administration
• 4.4 Marketed Drugs Profiles and Sales Forecasts

5 Pricing and Reimbursement Assessment

• 5.1 Annual Therapy Cost
• 5.2 Time to Pricing and Reimbursement

6 Pipeline Drugs Assessment

• 6.1 Phase III Pipeline Drugs
• 6.2 Overview by Development Stage
• 6.3 Overview by Molecule Type
• 6.4 Overview by Mechanism of Action
• 6.5 Overview by Route of Administration
• 6.6 Drug Specific Phase Transition Success Rate (PTSR) and Likelihood of Approval (LoA)
• 6.7 Therapy Area and Indication-specific PTSR and LoA

7 Clinical Trials Assessment

• 7.1 Historical Overview
• 7.2 Overview by Phase
• 7.3 Overview by Status
• 7.4 Overview by Phase for Ongoing and Planned Trials
• 7.5 Trials with Virtual Components
• 7.6 Geographic Overview
• 7.7 Single-Country and Multinational Trials by Region
• 7.8 Top 20 Sponsors with Breakdown by Phase
• 7.9 Top 20 Sponsors with Breakdown by Status
• 7.10 Overview by Endpoint Status
• 7.11 Overview by Race and Ethnicity
• 7.12 Enrollment Data
• 7.13 Top 20 countries for Trial Sites
• 7.14 Top 20 Sites Globally
• 7.15 Feasibility Analysis - Geographic Overview
• 7.16 Feasibility Analysis - Benchmark Models

8 Deals Landscape

• 8.1 Mergers, Acquisitions, and Strategic Alliances by Region
• 8.2 Recent Mergers, Acquisitions, and Strategic Alliances

9 Commercial Assessment

• 9.1 Key Market Players

10 Future Market Catalysts

11 Appendix

• 11.1 Methodology
• 11.2 Methodology - Sales Forecast
• 11.3 Methodology - Pricing and Reimbursement
• 11.4 Methodology - PTSR and LoA Analysis
• 11.5 About the Authors
• 11.6 Contact Us
• 11.7 Disclaimer